ArticleJACC. Asia2023

Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial.

Litong Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.